Purpose The use of two solvent-casted film methods to select optimal polymer compositions
for amorphous solid dispersions prepared to support preclinical pharmacokinetic and …

Amorphous solid dispersion (ASD) can accelerate a project by improving dissolution rate
and solubility, offering dose escalation flexibility and excipient acceptance for toxicology …

There has been an increasing interest in studying amorphous solid dispersion (ASD)
approaches in response to the increasing number of poorly soluble compounds from …

Miniaturised solvent casting (MSC) has been developed as a method for screening the
stability of amorphous solid dispersions (ASD) of BCS class II drugs. The aim of the work …

It is well recognized that poor dissolution rate and solubility of drug candidates are key
limiting factors for oral bioavailability. While numerous technologies have been developed to …

Poorly water-soluble drugs pose a significant challenge to developability due to poor oral
absorption leading to poor bioavailability. Several approaches exist that improve the oral …

Evolving therapeutic landscape through combinatorial chemistry and high throughput
screening have resulted in an increased number of poorly soluble drugs. Drug delivery …

To reduce the pill burden associated with amorphous solid dispersions (ASDs), which arises
from the large quantity of polymer used in the formulation, it is of interest to understand the …

Purpose To present a new screening methodology intended to be used in the early
development of spray-dried amorphous solid dispersions. Methods A model that combines …

Despite the fact that an amorphous solid dispersion (ASD)-coated pellet formulation offers
potential advantages regarding the minimization of physical stability issues, there is still a …